Landmark GLP-1 drug deal to improve US patients’ health and may boost Eli Lilly shares
A true landmark weight-loss drug deal by the Trump’s White House and the two providers Eli Lilly & Novo Nordisk was announced last Friday. Under the agreement, the major US government health insurance Medicare will provide coverage to 66 million members on the blockbuster weight-loss GLP-1 drugs Zepbound & Wegovy at much lower prices. On top, the government direct-to-customer channel will provide lower priced drugs to patient. This major agreement will bring access for tens of millions of people & patients that cannot afford these drugs before. Despite at lower prices, a much bigger market would boost unit and total sales of Eli Lilly & Novo Nordisk as well as other new providers.
Although there are some constraints, most Medicare members could be covered to expand their market of GLP-1 drugs from 8.5 million now to 40 million in 12-18 months. Instead of the high US$1,000 – US$1,300 per month, the government insurance would only need to pay US$350 or lower for future obesity pill and lower dosage later. This would only pressure other commercial insurance plans to provide coverage to their private members to boost the Total-Addressable-Market (TAM) even more. At the moment, only around 36% of private commercial health insurance plans provide some type of coverage to GLP-1 drugs.










